Home/Pipeline/MelCancerVac® (Technology Transfer/Manufacturing)

MelCancerVac® (Technology Transfer/Manufacturing)

Colorectal Cancer

Not Applicable (Client product)Active

Key Facts

Indication

Colorectal Cancer

Phase

Not Applicable (Client product)

Status

Active

Company

Cellin Technologies

About Cellin Technologies

Cellin Technologies is a private, revenue-generating CDMO focused on the high-growth cell therapy and regenerative medicine sector. The company provides essential GMP manufacturing and development services to biotech firms, helping to bridge the gap between research and clinical application. With a validated GMP facility, experienced personnel including a Qualified Person, and a history of handling proprietary technologies like MelCancerVac®, Cellin is positioned as a specialized partner for cell therapy developers in Europe. Its business model is purely service-based, offering flexibility and custom solutions to meet specific client needs.

View full company profile

Therapeutic Areas

Oncology Regenerative Medicine

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active
Program not named	Reponex	Pre-clinical	Active
Colorectal Cancer Screening Test	Metabiomics	Approved	Active